152 related articles for article (PubMed ID: 17729166)
1. CalcNTCP: a simple tool for computation of normal tissue complication probability (NTCP) associated with cancer radiotherapy.
Khan HA
Int J Radiat Biol; 2007 Oct; 83(10):717-20. PubMed ID: 17729166
[TBL] [Abstract][Full Text] [Related]
2. A free software for the evaluation and comparison of dose response models in clinical radiotherapy (DORES).
Tsougos I; Grout I; Theodorou K; Kappas C
Int J Radiat Biol; 2009 Mar; 85(3):227-37. PubMed ID: 19296336
[TBL] [Abstract][Full Text] [Related]
3. Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships.
El Naqa I; Suneja G; Lindsay PE; Hope AJ; Alaly JR; Vicic M; Bradley JD; Apte A; Deasy JO
Phys Med Biol; 2006 Nov; 51(22):5719-35. PubMed ID: 17068361
[TBL] [Abstract][Full Text] [Related]
4. Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease.
Cheng JC; Liu HS; Wu JK; Chung HW; Jan GJ
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1150-6. PubMed ID: 15990021
[TBL] [Abstract][Full Text] [Related]
5. Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data.
Semenenko VA; Li XA
Phys Med Biol; 2008 Feb; 53(3):737-55. PubMed ID: 18199912
[TBL] [Abstract][Full Text] [Related]
6. Extrapolation of normal tissue complication probability for different fractionations in liver irradiation.
Tai A; Erickson B; Li XA
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):283-9. PubMed ID: 19289259
[TBL] [Abstract][Full Text] [Related]
7. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma.
Xu ZY; Liang SX; Zhu J; Zhu XD; Zhao JD; Lu HJ; Yang YL; Chen L; Wang AY; Fu XL; Jiang GL
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):189-95. PubMed ID: 16542787
[TBL] [Abstract][Full Text] [Related]
8. TCP and NTCP: a basic introduction.
Baumann M; Petersen C
Rays; 2005; 30(2):99-104. PubMed ID: 16294901
[TBL] [Abstract][Full Text] [Related]
9. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD).
Luxton G; Keall PJ; King CR
Phys Med Biol; 2008 Jan; 53(1):23-36. PubMed ID: 18182685
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
[TBL] [Abstract][Full Text] [Related]
11. EUCLID: an outcome analysis tool for high-dimensional clinical studies.
Gayou O; Parda DS; Miften M
Phys Med Biol; 2007 Mar; 52(6):1705-19. PubMed ID: 17327657
[TBL] [Abstract][Full Text] [Related]
12. Tumor control probability (TCP) and normal tissue complication probability (NTCP) in head and neck cancer.
Grégoire V
Rays; 2005; 30(2):105-8. PubMed ID: 16294902
[TBL] [Abstract][Full Text] [Related]
13. Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
Tucker SL; Liu HH; Wang S; Wei X; Liao Z; Komaki R; Cox JD; Mohan R
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):754-61. PubMed ID: 16965865
[TBL] [Abstract][Full Text] [Related]
14. Preoperative radiation treatment for rectal cancer: comparison of target coverage and small bowel NTCP in conventional vs. 3D-conformal planning.
Cella L; Ciscognetti N; Martin G; Liuzzi R; Punzo G; Solla R; Farella A; Salvatore M; Pacelli R
Med Dosim; 2009; 34(1):75-81. PubMed ID: 19181259
[TBL] [Abstract][Full Text] [Related]
15. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy.
Dijkema T; Terhaard CH; Roesink JM; Braam PM; van Gils CH; Moerland MA; Raaijmakers CP
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1101-9. PubMed ID: 18472355
[TBL] [Abstract][Full Text] [Related]
16. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer.
Strigari L; Arcangeli G; Arcangeli S; Benassi M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1454-60. PubMed ID: 18990503
[TBL] [Abstract][Full Text] [Related]
17. Convex reformulation of biologically-based multi-criteria intensity-modulated radiation therapy optimization including fractionation effects.
Hoffmann AL; den Hertog D; Siem AY; Kaanders JH; Huizenga H
Phys Med Biol; 2008 Nov; 53(22):6345-62. PubMed ID: 18941280
[TBL] [Abstract][Full Text] [Related]
18. A simple method to calculate the influence of dose inhomogeneity and fractionation in normal tissue complication probability evaluation.
Begnozzi L; Gentile FP; Di Nallo AM; Chiatti L; Zicari C; Consorti R; Benassi M
Strahlenther Onkol; 1994 Oct; 170(10):590-4. PubMed ID: 7974170
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the 3D-conformal, helical tomotherapy and multileaf collimators-based intensity modulated radiotherapy modalities using radiobiological measures.
Mavroidis P; Costa Ferreira B; Shi C; Lind BK; Papanikolaou N
J BUON; 2008; 13(1):75-86. PubMed ID: 18404791
[TBL] [Abstract][Full Text] [Related]
20. Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation.
Tai A; Erickson B; Khater KA; Li XA
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):900-7. PubMed ID: 18262101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
